Verge Labs launches AI tool to boost patient enrollment and trial efficiency; Moderna appoints new chief commercial officer

Verge Labs announced a new artificial‑intelligence model designed to identify patients most likely to respond to a therapy, aiming to reduce dropout rates and increase the statistical power of clinical trials.

The company says the tool will help trial sponsors select participants more effectively, potentially shortening study timelines and lowering costs.

In related news, Moderna named Ester Banque as its chief commercial officer. Banque previously led U.S. operations at Zoetis.

Moderna President Stephen Hoge also received an expanded portfolio, overseeing several of the company’s drug development programs.